Group 1 - The annual press conference is being held, welcoming both in-person and virtual journalists despite traffic difficulties [1] - The CFO, Nadia Jakobi, and CEO, Leonhard Birnbaum, are present to provide an overview of the past fiscal year [2]

Core Viewpoint - FMC is recognized as a fundamentally important player in the agriculture market, highlighting its long-standing participation in industry conferences and events [1]. Group 1 - The business has experienced significant developments both fundamentally and strategically, indicating ongoing changes and adaptations within the company [2].

FMC (NYSE:FMC) 2026 Conference February 25, 2026 02:45 PM ET Company ParticipantsAndrew Sandifer - EVP and CFOPierre Brondeau - Chairman, President, and CEOConference Call ParticipantsNone - AnalystNone - AnalystModeratorWelcome back, everybody. As we kind of move into the afternoon, I'm pleased to be welcoming Pierre Brondeau, CEO and President of FMC, and Andrew Sandifer, who's EVP and CFO. You know, FMC been a long-standing participant in the conference and obviously a very fundamentally important player ...

About FMC PHILADELPHIA, Feb. 23, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) announced that the Herbicide Resistance Action Committee (HRAC) has classified rimisoxafen as a dual mode of action herbicide, designated under HRAC Groups 12 and 32. This is the first dual mode of action classification in HRAC's history, a significant milestone for the global crop protection industry and validation of FMC's innovative approach to combating herbicide-resistant weeds. The unprecedented classification recognizes ...

Core Viewpoint - FMC Corporation's stock has significantly declined following poor Q3 earnings and continued challenges in Q4, leading to a cautious outlook for investors [1][2]. Financial Performance - Q3 earnings revealed a 49% drop in sales, resulting in a loss of $4.52 per share, and a full-year revenue decline of 18% in 2025 [1][5]. - Q4 earnings missed revenue expectations, with management forecasting a further 5% decline in revenue to approximately $3.7 billion in 2026 and a 41% decline in adjusted EBITDA [2][8]. Stock Performance - Since the Q3 earnings report, FMC stock has stabilized, trading between $13 and $17, currently priced around $14.50 [3][8]. - The market capitalization of FMC is approximately $1.8 billion, with a current price-to-free cash flow ratio of 30 times, indicating a potentially expensive valuation given the debt load [8][9]. Strategic Options - FMC is exploring strategic options to maximize shareholder value, including the potential sale of the company [6]. - The company plans to raise $1 billion through asset sales and licensing agreements to reduce its debt, which currently exceeds cash by $3.5 billion [6]. Product Development - FMC is set to commercialize four new herbicides and fungicides, which may contribute to future revenue growth [7].

Core Viewpoint - The article discusses the investment positions held by the author in specific companies, indicating a long position in YARIY and BAYZF, which may suggest a positive outlook on these stocks [1]. Group 1 - The author has a beneficial long position in the shares of YARIY and BAYZF, either through stock ownership, options, or other derivatives [1]. - The article expresses the author's personal opinions and is not receiving compensation for it, aside from Seeking Alpha [1]. Group 2 - The article emphasizes that it should not be considered financial advice, as the author is not a licensed financial advisor [2]. - Investors are encouraged to conduct their own due diligence and research prior to making any investment decisions [2]. - The article highlights the risks associated with short-term trading, options trading, and futures trading, which may not be suitable for all investors [2].

Core Viewpoint - FMC Corporation will participate in the Bank of America Global Agriculture and Materials Conference on February 25, 2026, where CEO Pierre Brondeau and CFO Andrew Sandifer will speak, highlighting the company's commitment to agricultural innovation and sustainability [1]. Group 1: Company Overview - FMC Corporation is a global agricultural sciences company focused on helping growers produce food, feed, fiber, and fuel for a growing population while adapting to environmental changes [1]. - The company offers innovative crop protection solutions, including biologicals, crop nutrition, and digital and precision agriculture, aimed at addressing economic challenges while protecting the environment [1]. Group 2: Strategic Initiatives - FMC Corporation has set its priorities for 2026 and has received authorization from its Board to explore strategic options, which may include the sale of the company [1].

Group 1 - FMC Corp. reported Q4 2025 sales of $1.08 billion, a decrease of 11% year over year, with adjusted EBITDA of $280 million, down 17%, and adjusted EPS of $1.20, down 33% [1] - For 2026, FMC projects full-year sales between $3.6 billion and $3.8 billion, with adjusted EBITDA expected to be between $670 million and $730 million, while Q1 sales are anticipated to decline by around 5% and EBITDA by nearly 60% year over year due to one-off costs and tariff headwinds [3] - The company expects approximately $20 million in tariff-related headwinds in 2026, primarily impacting the first quarter [3] Group 2 - Moody's downgraded FMC's senior unsecured ratings to Ba1 from Baa3, resulting in junk status, and assigned a negative outlook due to challenges from patent expirations of its insect-control product Rynaxypyr in multiple countries [4] - FMC is an agricultural sciences company focused on crop protection, plant health, agriculture, pest control, and turf management, offering a range of products including insect control products, herbicides, insecticides, flutriafol-based fungicides, and bionematicides [5]

Core Viewpoint - FMC Corporation is exploring various strategic options, including the potential sale of the company, due to significant operational challenges and financial losses [1] Group 1: Financial Performance - FMC reported a revenue of $3.47 billion for 2025, a decrease of 18% year-over-year, primarily due to a 6% decline in product prices [1] - The company experienced a net loss of $2.24 billion, which is a reduction of $2.58 billion compared to the previous year [1] - For 2026, FMC projects revenue between $3.6 billion and $3.8 billion, representing a year-over-year growth of 4% to 10% [2] Group 2: Strategic Challenges - The expiration of the patent for the insecticide Rynaxypyr has placed FMC under dual pressure in both strategic and operational aspects [1] - Ongoing debt issues have constrained FMC's development, leading to a downgrade in its credit rating from BBB- to BB+ by S&P Global Ratings, placing it in the non-investment grade category [1] - The company faces long-term competition from generic products, particularly low-priced offerings in Latin America and Asia, which impact pricing strategies and profit margins [1] Group 3: Strategic Initiatives - FMC is advancing its 2026 operational plan, which includes asset sales and licensing agreements aimed at repaying $1 billion in debt and optimizing its balance sheet [1] - The company has identified four new active ingredients and product lines that are unique and disruptive, with plans to increase investment in these technologies to enhance business growth and financial performance [1] - The strategic evaluation is still in the preliminary stage, and there is no assurance that any transactions will be finalized [1]

Core Viewpoint - Morgan Stanley has lowered its price target on FMC to $15.50 from $17 while maintaining an Equal Weight rating on the shares [1] Group 1: Price Target and Rating - The price target for FMC has been reduced to $15.50 from $17 [1] - Morgan Stanley continues to hold an Equal Weight rating on FMC shares [1] Group 2: Future Outlook - The firm has lowered its estimates but believes that the most likely outcome for FMC involves a joint venture or license agreement concerning its four new patented molecules [1] - There is potential for co-development of the remaining R&D pipeline as part of this outcome [1]